3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Breast Neoplasms
27
Neoplasms
25
Lung Neoplasms
12
Uterine Cervical Neoplasms
11
Colorectal Neoplasms
10
Colonic Neoplasms
8
Motor Activity
7
Urinary Bladder Neoplasms
6
Rectal Neoplasms
6
Vulvar Neoplasms
5
Obesity
5
Endometrial Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Head and Neck Neoplasms
4
Anxiety Disorders
4
Stomach Neoplasms
3
Sarcoma
3
Prostatic Neoplasms
3
Papillomavirus Infections
3
Lymphoma
3
Hematopoietic and Lymphoid System Neoplasm
3
Hematologic Neoplasms
3
Depression
3
Carcinoma, Ovarian Epithelial
3
Breast Carcinoma In Situ
3
Vaginal Neoplasms
2
Testicular Neoplasms
2
Smoking Cessation
2
Skin Neoplasms
2
Interventions
Everolimus
7
avelumab
3
Temozolomide
3
Etoposide
3
Cisplatin
3
Bevacizumab
3
pembrolizumab
2
gallium Ga 68 dotatate
2
azaspirane
2
Irinotecan
2
veliparib
1
tocilizumab
1
selinexor
1
pralsetinib
1
pertuzumab
1
pasireotide
1
lenvatinib
1
irinotecan sucrosofate
1
carfilzomib
1
berzosertib
1
belinostat
1
Topotecan
1
TLC 388
1
Radiotherapy
1
Radiosurgery
1
Radionuclide Imaging
1
Positron-Emission Tomography
1
Positron Emission Tomography Computed Tomography
1
Podophyllotoxin
1
Platinum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Neuroendocrine
×
Methods
×
Clear all
NCT04478175
2022-11-17
DParcoursDig
Institut Curie
Phase NA
Completed
30 enrolled